# Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

> **NCT00142480** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 8 (actual)

## Conditions studied

- Biliary Tract Cancer
- Gallbladder Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab
- **PROCEDURE:** Radiation therapy

## Key facts

- **NCT ID:** NCT00142480
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-07
- **Final completion:** 2011-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-04-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142480, "Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00142480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*